NCT06136624 2026-03-11
OMAHA-003
Merck Sharp & Dohme LLC
Phase 3 Recruiting
Clinical Trials
15 trialsNCT02825628 2024-08-29
CRPC
DexTech Medical AB
Phase 2 Completed
NCT03850795 2024-08-19
HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Hinova Pharmaceuticals USA, Inc.
Phase 3 Terminated
NCT04028388 2024-04-17
ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer
Modra Pharmaceuticals
Phase 2 Completed
NCT03575819 2024-02-01
A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Fortis Therapeutics, Inc.
Phase 1 Completed
NCT02485691 2022-05-27
CARD
Sanofi
Phase 4 Completed
NCT03646162 2021-12-03
Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer
Veru Inc.
Phase 2 Completed
NCT02407054 2021-05-11
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
Eli Lilly and Company
Phase 2 Completed
NCT04603833 2021-02-21
A Study of SHR3680 in Combination With Docetaxel in the Treatment of mCRPC
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Unknown
NCT02379390 2019-06-21
PRIMCAB
Sanofi
Phase 2 Terminated
NCT01718353 2017-11-20
TAXYNERGY
Sanofi
Phase 2 Completed
NCT02378870 2016-06-30
A Phase IIb Study to Evaluate Efficacy and Tolerability of ODX (Osteodex) in Metastatic CRPC
DexTech Medical AB
Phase 2 Terminated
NCT02074137 2016-06-02
Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer
Sanofi
Phase 4 Completed
NCT01254279 2015-01-21
Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen
Sanofi
Phase 3 Completed
NCT01595087 2014-11-14
A Phase I/II Study of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC)
DexTech Medical AB
Phase 1/2 Completed